Sign up Australia
Proactive Investors - Run By Investors For Investors

AuMake International acquires stake in valerian root milk firm Herbsmart Pharmaceutical

The milk will be promoted on China’s JiaJia TV shopping channel which has 385 million viewers.
Valerian milk product
Valerian milk product combine the health benefits of natural supplements and milk

AuMake International Ltd (ASX:AU8) has acquired 50% of Herbsmart Pharmaceutical, a company supplying milk containing valerian root.

Herbsmart’s range consists of speciality milk products with planned product development, contemporary design and packaging to focus on the needs of China’s ageing population.

AuMake connects local suppliers in Australia with daigou - who buy products for customers in mainland China - and Chinese tourists.

The addition of Herbsmart further expands AuMake’s portfolio of owned brands and is the first owned brand dairy product.

READ: AuMake International snaps up Kiwi Buy to enhance Chinese targeted sales strategy

Stocked in AuMake since October 2017, the Herbsmart brand is growing in awareness among the daigou and Chinese tourist markets.

Herbsmart valerian milk uses valerian root and other natural supplements that are specially formulated to aid sleep.

AuMake’s purchase of the 50% stake is at nil cost, in recognition of its contribution to the development of the Herbsmart brand.

The deal also gives an option for AuMake to buy a further 40% in Herbsmart.

AuMake executive chairman Keong Chan said: “Our observation of current trends and market feedback from our customers in Australia and China indicates that a significant opportunity exists for AuMake to develop a range of products, starting with the Valerian milk product, which combine the health benefits of natural supplements and milk.

“Our initial joint ownership and opportunity to acquire more of Herbsmart provides a strategic opportunity for us to develop niche products to meet an identified need within the Chinese consumer market, with 241 million Chinese over the age of 60 and that number expected to rise to 487 million by 2050.”

View full AU8 profile View Profile

AuMake International Ltd Timeline

Related Articles

Once the phase III trial is completed, Futura plans to either sell off the asset or find a partner
September 26 2018
The pharma group expects to dose the first patient in the Phase III trial of its MED2002 erectile dysfunction treatment within the next month
scientist in lab
September 11 2018
The phase 1b trial of Silence’s lead candidate, SLN124, a treatment for a rare blood disorder, is scheduled to begin in the second half of 2019
little girl sneezing in a field
May 21 2018
The Phase II study of Allergy Therapeutics’ PQ Grass immunotherapy – an aluminium-free, ultra-short course hay fever treatment – evaluated dose response and safety

No investment advice

The information on this Site is of a general nature only. It does not take your specific needs or circumstances into consideration, so you should look at your own financial position, objectives and requirements and seek financial advice before making any financial decisions. You acknowledge and understand that neither the Company, its related bodies corporate, the information providers or their affiliates will advise you personally about the nature, potential value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter. You should read our FSG and any other relevant disclosure documents and if necessary seek persona advice prior to making any investment decision.

You understand and agree that no Content (as defined below) published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person.

You understand that in certain circumstances the Company, its related bodies corporate, the information providers or their affiliates may have received, or be entitled to receive, financial or other consideration in connection with promoting, and providing information about, certain entities on the Site and in communications otherwise provided to you.

You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate. From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Before you act on any general advice we provide, please consider whether it is appropriate for your personal circumstances.

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use